Effects of estrogens on atherogenesis

Current Vascular Pharmacology

Volumn 9, Issue 2, 2011, Pages 244-257

  Kolovou, Genovefa ^a   Giannakopoulou, Vasiliki ^a   Vasiliadis, Yannis ^a   Bilianou, Helen ^b  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

Author keywords

Atherogenesis; Cardiovascular disease; Estrogens; Genes promoting atherogenesis; Hormone replacement therapy; Women

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN E; CHOLESTEROL ESTER TRANSFER PROTEIN; CHORIONIC GONADOTROPIN; ENDOSTATIN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; METALLOPROTEINASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROLIFERIN; RALOXIFENE; SCATTER FACTOR; SITOSTEROL; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR ALPHA; TRIACYLGLYCEROL; VASCULAR ADHESION PROTEIN 1; VASCULOTROPIN;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BREAST CANCER; CELL ADHESION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL FEATURE; DISEASE COURSE; DNA POLYMORPHISM; DRUG RECEPTOR BINDING; ESTROGEN BLOOD LEVEL; ESTROGEN RESPONSIVE ELEMENT; ESTROGEN THERAPY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC ASSOCIATION; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID METABOLISM; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTMENOPAUSE; REVIEW; RNA SPLICING; SITOSTEROLEMIA; SPINE FRACTURE; STROKE; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ANIMALS; ATHEROSCLEROSIS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MALE; RISK FACTORS;

EID: 79951685292     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016111794519327     Document Type: Review

References (219)

1. Mosca L, Grundy SM, Judelson D, et al. Guide to Preventive Cardiology for Women.AHA/ACC Scientific Statement Consensus panel statement. Circulation 1999; 99: 2480-4.
2. Mosca L, Appel LJ, Benjamin EJ, et al. Summary of the American Heart Association's evidence-based guidelines for CVD prevention in women. Arterioscler Thromb Vasc Biol 2004; 24: 394-6.
3. Wingo PA, Calle EE, McTiernan A. How does breast cancer mortality compare with that of other cancers and selected CVDs at different ages in U.S. women? J Women Health Gender Based Med 2000; 9: 999-1006.
4. de Kleijn MJ, van der Schouw YT, van der Graaf Y. Reproductive history and CVD risk in postmenopausal women: a review of the literature. Maturitas 1999; 33: 7-36.
5. Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Early menopause and the risk of MI. Am J Obstet Gynecol 1981; 139: 47-51.
6. Cooper GS, Baird DD, Weinberg CR, Ephross SA, Sandler DP. Age at menopause and childbearing patterns in relation to mortality. Am J Epidemiol 2000; 151: 620-3.
7. Fioretti F, Tavani A, Gallus S, Franceschi S, La Vecchia C. Menopause and risk of non-fatal acute MI: an Italian case-control study and a review of the literature. Hum Reprod 2000; 15: 599-603.
8. van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996; 347: 714-8.
9. Jacobsen BK, Knutsen SF, Fraser GE. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J Clin Epidemiol 1999; 52: 303-7.
10. Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999; 159: 1061-6.
11. Saltiki K, Doukas C, Kanakakis J, Anastasiou E, Mantzou E, Alevizaki M. Severity of cardiovascular disease in women: relation with exposure to endogenous estrogen. Maturitas 2006; 55: 51-7.
12. de Kleijn MJ, van der Schouw YT, Verbeek AL, Peeters PH, Banga JD, van der Graaf Y. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol 2002; 155: 339-45.
13. Jansen SC, Temme EH, Schouten EG. Lifetime estrogen exposure vs. age at menopause as mortality predictor. Maturitas 2002; 43: 105-12.
14. Tokunaga O, Fan JL, Watanabe T. Atherosclerosis- and age-related multinucleated variant endothelial cells in primary culture from human aorta. Am J Pathol 1989; 135: 967-76.
15. Elkeles A. Observations on the natural history of atherogenesis. J Am Geriatr Soc 1976; 24: 58-64.
16. Weber G, Bianciardi G, Bussani R, et al. Atherosclerosis and aging. A morphometric study on arterial lesions of elderly and very elderly necropsy subjects. Arch Pathol Lab Med 1988; 112: 1066-70.
17. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inacti vated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A 1992; 89: 4471-5.
18. Powell-Braxton L, Veniant M, Latvala RD, et al. A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nat Med 1998; 4: 934-8.
19. Kolovou G, Anagnostopoulou K, Mikhailidis DP, Cokkinos DV. Apolipoprotein E knockout models. Curr Pharm Des 2008; 14: 338-51.
20. Bonthu S, Heistad DD, Chappell DA, Lamping KG, Faraci FM. Atherosclerosis, vascular remodeling, and impairment of endothelium- dependent relaxation in genetically altered hyperlipidemic mice. Arterioscler Thromb Vasc Biol 1997; 17: 2333-40.
21. d'Uscio LV, Baker TA, Mantilla CB, et al. Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 1017-22.
22. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-71.
23. Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-Edeficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 2004; 24: 1006-14.
24. Choi J, Forster MJ, McDonald SR, Weintraub ST, Carroll CA, Gracy RW. Proteomic identification of specific oxidized proteins in ApoE-knockout mice: relevance to Alzheimer's disease. Free Radic Biol Med 2004; 36: 1155-62.
25. Crisby M, Rahman SM, Sylven C, Winblad B, Schultzberg M. Effects of high cholesterol diet on gliosis in apolipoprotein E knockout mice. Implications for Alzheimer's disease and stroke. Neurosci Lett 2004; 369: 87-92.
26. Behr-Roussel D, Darblade B, Oudot A, et al. Erectile dysfunction in hypercholesterolemic atherosclerotic apolipoprotein E knockout mice. J Sex Med 2006; 3: 596-603.
27. Ezzahiri R, Stassen FR, Kurvers HA, van Pul MM, Kitslaar PJ, Bruggeman CA. Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice. Eur J Vasc Endovasc Surg 2003; 26: 88-95.
28. Hsich E, Zhou YF, Paigen B, Johnson TM, Burnett MS, Epstein SE. Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. Atherosclerosis 2001; 156: 23-8.
29. Liuba P, Karnani P, Pesonen E, et al. Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein Eknockout mice. Circulation 2000; 102: 1039-44.
30. Schwedler SB, Amann K, Wernicke K, et al. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 2005; 112: 1016-23.
31. Tous M, Ferre N, Camps J, Riu F, Joven J. Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis. Mol Cell Biochem 2005; 268: 53-8.
32. Ali ZA, Alp NJ, Lupton H, et al. Increased in-stent stenosis in ApoE knockout mice: insights from a novel mouse model of balloon angioplasty and stenting. Arterioscler Thromb Vasc Biol 2007; 27: 833-40.
33. Matter CM, Ma L, von Lukowicz T, et al. Increased ballooninduced inflammation, proliferation, and neointima formation in apolipoprotein E (ApoE) knockout mice. Stroke 2006; 37: 2625-32.
34. Tabas I. Cholesterol in health and disease. J Clin Invest 2002; 110: 583-90.
35. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. J Lipid Res 2005; 46: 179-90.
36. Westhuyzen J. The oxidation hypothesis of atherosclerosis: an update. Ann Clin Lab Sci 1997; 27: 1-10.
37. Xu XP, Meisel SR, Ong JM, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999; 99: 993-8.
38. Heinecke JW. Pathways for oxidation of low density lipoprotein by myeloperoxidase: tyrosyl radical, reactive aldehydes, hypochlorous acid and molecular chlorine. Biofactors 1997; 6: 145-55.
39. Hakala JK, Lindstedt KA, Kovanen PT, Pentikainen MO. Lowdensity lipoprotein modified by macrophage-derived lysosomal hydrolases induces expression and secretion of IL-8 via p38 MAPK and NF-kappaB by human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 2006; 26: 2504-9.
40. Gois J, Higuchi M, Reis M, et al. Infectious agents, inflammation, and growth factors: how do they interact in the progression or stabilization of mild human atherosclerotic lesions? Ann Vasc Surg 2006; 20: 638-45.
41. Orekhov AN, Andreeva ER, Mikhailova IA, Gordon D. Cell proliferation in normal and atherosclerotic human aorta: proliferative splash in lipid-rich lesions. Atherosclerosis 1998; 139: 41-8.
42. Andreeva ER, Pugach IM, Orekhov AN. Collagen-synthesizing cells in initial and advanced atherosclerotic lesions of human aorta. Atherosclerosis 1997; 130: 133-42.
43. Chatzizisis YS, Jonas M, Coskun AU, et al. Prediction of the localization of high-risk coronary atherosclerotic plaques on the basis of low endothelial shear stress: an intravascular ultrasound and histopathology natural history study. Circulation 2008; 117: 993-1002.
44. Ardans JA, Blum A, Mangan PR, Wientroub S, Cannon RO, 3rd, Wahl LM. Raloxifene-mediated increase in matrix metalloproteinase-1 production by activated monocytes. Arterioscler Thromb Vasc Biol 2001; 21: 1265-8.
45. Mudali S, Dobs AS, Ding J, Cauley JA, Szklo M, Golden SH. Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study. J Clin Endocrinol Metab 2005; 90: 1202-9.
46. Mueck AO, Seeger H, Wallwiener D. Medroxyprogesterone acetate vs. norethisterone: effect on estradiol-induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. Menopause 2002; 9: 273-81.
47. Rosenfeld ME, Kauser K, Martin-McNulty B, Polinsky P, Schwartz SM, Rubanyi GM. Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice. Atherosclerosis 2002; 164: 251-9.
48. Elhage R, Gourdy P, Jawien J, et al. The atheroprotective effect of 17beta-estradiol depends on complex interactions in adaptive immunity. Am J Pathol 2005; 167: 267-74.
49. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A 1995; 92: 8264-8.
50. Arnal JF, Douin-Echinard V, Tremollieres F, et al. Understanding the controversy about hormonal replacement therapy: insights from estrogen effects on experimental and clinical atherosclerosis. Arch Mal Coeur Vaiss 2007; 100: 554-62.
51. Ribichini F, Joner M, Ferrero V, et al. Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. J Am Coll Cardiol 2007; 50: 176-85.
52. Braunersreuther V, Mach F. Leukocyte recruitment in atherosclerosis: potential targets for therapeutic approaches? Cell Mol Life Sci 2006; 63: 2079-88.
53. Zernecke A, Weber C. Inflammatory mediators in atherosclerotic vascular disease. Basic Res Cardiol 2005; 100: 93-101.
54. Zandbergen F, Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta 2007; 1771: 972-82.
55. Cheng C, Tempel D, van Haperen R, et al. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 2006; 113: 2744-53.
56. Liehn EA, Zernecke A, Postea O, Weber C. Chemokines: inflammatory mediators of atherosclerosis. Arch Physiol Biochem 2006; 112: 229-38.
57. Dabek J, Kulach A, Gasior Z. The role of matrix metalloproteinases in acute coronary syndromes. Eur J Intern Med 2007; 18: 463-6.
58. Goncalves I, Ares MP, Moberg A, et al. Elastin- and collagen-rich human carotid plaques have increased levels of the cysteine protease inhibitor cystatin C. J Vasc Res 2008; 45: 395-401.
59. Yamada S, Wang KY, Tanimoto A, et al. Matrix metalloproteinase 12 accelerates the initiation of atherosclerosis and stimulates the progression of fatty streaks to fibrous plaques in transgenic rabbits. Am J Pathol 2008; 172: 1419-29.
60. Lancelot E, Amirbekian V, Brigger I, et al. Evaluation of matrix metalloproteinases in atherosclerosis using a novel non-invasive imaging approach. Arterioscler Thromb Vasc Biol 2008; 28: 425-32.
61. Suzuki H, Kusuyama T, Sato R, et al. Elevation of matrix metalloproteinases and interleukin-6 in the culprit coronary artery of MI. Eur J Clin Invest 2008; 38: 166-73.
62. Heikkila HM, Latti S, Leskinen MJ, Hakala JK, Kovanen PT, Lindstedt KA. Activated mast cells induce endothelial cell apoptosis by a combined action of chymase and tumor necrosis factoralpha. Arterioscler Thromb Vasc Biol 2008; 28: 309-14.
63. Kovanen PT. Mast cells and degradation of pericellular and extracellular matrices: potential contributions to erosion, rupture and intraplaque haemorrhage of atherosclerotic plaques. Biochem Soc Trans 2007; 35: 857-61.
64. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007; 27: 15-26.
65. Bot I, de Jager SC, Zernecke A, et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation 2007; 115: 2516-25.
66. Lappalainen H, Laine P, Pentikainen MO, Sajantila A, Kovanen PT. Mast cells in neovascularized human coronary plaques store and secrete basic fibroblast growth factor, a potent angiogenic mediator. Arterioscler Thromb Vasc Biol 2004; 24: 1880-5.
67. Ribatti D, Levi-Schaffer F, Kovanen PT. Inflammatory angiogenesis in atherogenesis-a double-edged sword. Ann Med 2008; 40: 606-21.
68. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 2008; 263: 517-27.
69. Bobryshev YV. Calcification of elastic fibers in human atherosclerotic plaque. Atherosclerosis 2005; 180: 293-303.
70. Arnal JF, Scarabin PY, Tremollieres F, Laurell H, Gourdy P. Estrogens in vascular biology and disease: where do we stand today? Curr Opin Lipidol 2007; 18: 554-60.
71. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 2007; 14: 373-84.
72. Christersson C, Johnell M, Siegbahn A. Tissue factor and IL8 production by P-selectin-dependent platelet-monocyte aggregates in whole blood involves phosphorylation of Lyn and is inhibited by IL10. J Thromb Haemost 2008; 6: 986-94.
73. von Wnuck Lipinski K, Keul P, Ferri N, et al. Integrin-mediated transcriptional activation of inhibitor of apoptosis proteins protects smooth muscle cells against apoptosis induced by degraded collagen. Circ Res 2006; 98: 1490-7.
74. Ichiki T, Jougasaki M, Setoguchi M, et al. Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells. Am J Physiol Heart Circ Physiol 2008; 294: H750-63.
75. Preiss DJ, Sattar N. Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? Int J Clin Pract 2007; 61: 697-701.
76. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.
77. Gourdy P, Mallat Z, Castano C, et al. The atheroprotective effect of 17 beta-estradiol is not altered in P-selectin- or ICAM-1-deficient hypercholesterolemic mice. Atherosclerosis 2003; 166: 41-8.
78. Fitzpatrick LA, Ruan M, Anderson J, Moraghan T, Miller V. Gender- related differences in vascular smooth muscle cell proliferation: implications for prevention of atherosclerosis. Lupus 1999; 8: 397-401.
79. Sullivan TR, Jr., Karas RH, Aronovitz M, et al. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 1995; 96: 2482-8.
80. Iafrati MD, Karas RH, Aronovitz M, et al. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med 1997; 3: 545-8.
81. Miller VM, Duckles SP. Vascular actions of estrogens: functional implications. Pharmacol Rev 2008; 60: 210-41.
82. Fraser HM, Wilson H, Silvestri A, Morris KD, Wiegand SJ. The role of vascular endothelial growth factor and estradiol in the regulation of endometrial angiogenesis and cell proliferation in the marmoset. Endocrinology 2008; 149: 4413-20.
83. Reynolds LP, Killilea SD, Redmer DA. Angiogenesis in the female reproductive system. FASEB J 1992; 6: 886-92.
84. Sharp PS. The role of growth factors in the development of diabetic retinopathy. Metabolism 1995; 44(10 Suppl 4): 72-5.
85. Nickoloff BJ, Mitra RS, Varani J, Dixit VM, Polverini PJ. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994; 144: 820-8.
86. Kim KH, Moriarty K, Bender JR. Vascular cell signaling by membrane estrogen receptors. Steroids 2008; 73: 864-9.
87. Turner HE, Harris AL, Melmed S, Wass JA. Angiogenesis in endocrine tumors. Endocr Rev 2003; 24: 600-32.
88. Hyder SM, Nawaz Z, Chiappetta C, Stancel GM. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 2000; 60: 3183-90.
89. Leclercq A, Houard X, Philippe M, et al. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J Leukoc Biol 2007; 82: 1420-9.
90. Lewandowski KC, Komorowski J, Mikhalidis DP, et al. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab 2006; 91: 3123-30.
91. Bobryshev YV, Killingsworth MC, Lord RS, Grabs AJ. Matrix vesicles in the fibrous cap of atherosclerotic plaque: Possible contribution to plaque rupture. J Cell Mol Med 2008; 12: 2073-82.
92. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007; 17: 253-8.
93. Oviedo-Orta E, Bermudez-Fajardo A, Karanam S, Benbow U, Newby AC. Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. Immunology 2008; 124: 42-50.
94. Fukuda D, Shimada K, Tanaka A, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute MI vs. unstable angina pectoris vs. stable angina pectoris. Am J Cardiol 2006; 97: 175-80.
95. Cheng M, Hashmi S, Mao X, Zeng QT. Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. Can J Cardiol 2008; 24: 385-90.
96. Goldman S, Shalev E. MMPS and TIMPS in ovarian physiology and pathophysiology. Front Biosci 2004; 9: 2474-83.
97. Curry TE, Jr., Song L, Wheeler SE. Cellular localization of gelatinases and tissue inhibitors of metalloproteinases during follicular growth, ovulation, and early luteal formation in the rat. Biol Reprod 2001; 65: 855-65.
98. Chun SY, Popliker M, Reich R, Tsafriri A. Localization of preovulatory expression of plasminogen activator inhibitor type-1 and tissue inhibitor of metalloproteinase type-1 mRNAs in the rat ovary. Biol Reprod 1992; 47: 245-53.
99. Aston KE, Stamouli A, Thomas EJ, et al. Effect of gonadotrophin on cell and matrix retention and expression of metalloproteinases and their inhibitor in cultured human granulosa cells modelling corpus luteum function. Mol Hum Reprod 1996; 2: 26-30.
100. Shalev E, Goldman S, Ben-Shlomo I. The balance between MMP-9 and MMP-2 and their tissue inhibitor (TIMP)-1 in luteinized granulosa cells: comparison between women with PCOS and normal ovulatory women. Mol Hum Reprod 2001; 7: 325-31.
101. Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 2000; 17: 673-81.
102. Okamoto T, Niu R, Yamada S. Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary. Mol Hum Reprod 2003; 9: 569-75.
103. Halapas A, Zacharoulis A, Theocharis S, et al. Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute MI. Clin Chem Lab Med 2008; 46: 510-6.
104. Shah PK. Plaque disruption and thrombosis: potential role of inflammation and infection. Cardiol Rev 2000; 8: 31-9.
105. Grandas OH, Mountain DJ, Kirkpatrick SS, et al. Effect of hormones on matrix metalloproteinases gene regulation in human aortic smooth muscle cells. J Surg Res 2008; 148: 94-9.
106. Henriksson P, Samnegard A, Wallen NH. Sex hormone sensitivity of matrix metalloproteinases 6 and 9. Eur J Clin Invest 2008; 38: 336-7.
107. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-83.
108. Folkesson M, Kazi M, Zhu C, et al. Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurysms. Thromb Haemost 2007; 98: 427-33.
109. Hemdahl AL, Gabrielsen A, Zhu C, et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and MI. Arterioscler Thromb Vasc Biol 2006; 26: 136-42.
110. Bu DX, Hemdahl AL, Gabrielsen A, et al. Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. Am J Pathol 2006; 169: 2245-53.
111. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 2006; 26: 287-92.
112. Cowland JB, Muta T, Borregaard N. IL-1beta-specific upregulation of neutrophil gelatinase-associated lipocalin is controlled by IkappaB-zeta. J Immunol 2006; 176: 5559-66.
113. Bracamonte MP, Miller VM. Vascular effects of estrogens: arterial protection vs. venous thrombotic risk. Trends Endocrinol Metab 2001; 12: 204-9.
114. Koh KK. Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women. Int J Hematol 2002; 76 (Suppl 2): 44-6.
115. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol 2005; 96: 53E-9E.
116. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-32.
117. Kruth HS, Huang W, Ishii I, Zhang WY. Macrophage foam cell formation with native low density lipoprotein. J Biol Chem 2002; 277: 34573-80.
118. Ishii I, Satoh H, Kawachi H, et al. Intimal smooth muscle cells upregulate beta-very low density lipoprotein-mediated cholesterol accumulation by enhancing beta-very low density lipoprotein uptake and decreasing cholesterol efflux. Biochim Biophys Acta 2002; 1585: 30-8.
119. Kapur NK, Ashen D, Blumenthal RS. High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. Vasc Health Risk Manag 2008; 4: 39-57.
120. Sendra J, Llorente-Cortes V, Costales P, Huesca-Gomez C, Badimon L. Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension. Cardiovasc Res 2008; 78: 581-9.
121. Landmesser U, Drexler H. Endothelial function and hypertension. Curr Opin Cardiol 2007; 22: 316-20.
122. Lang NN, Gudmundsdottir IJ, Boon NA, Ludlam CA, Fox KA, Newby DE. Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers: smoking, thrombin, and vascular responses in vivo. J Am Coll Cardiol 2008; 52: 33-9.
123. Shiu SW, Tan KC, Wong Y, Leng L, Bucala R. Glycoxidized LDL increases lectin-like oxidized low density lipoprotein receptor-1 in diabetes mellitus. Atherosclerosis 2008; 203: 522-7.
124. Yasar AS, Turhan H, Basar N, et al. Comparison of major coronary risk factors in female and male patients with premature coronary artery disease. Acta Cardiol 2008; 63: 19-25.
125. Linsel-Nitschke P, Gotz A, Erdmann J, et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease--a Mendelian Randomisation study. PLoS ONE 2008; 3: e2986.
126. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007; 4: 214-25.
127. Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006; 43: 943-9.
128. Norman D, Sun XM, Bourbon M, Knight BL, Naoumova RP, Soutar AK. Characterization of a novel cellular defect in patients with phenotypic homozygous familial hypercholesterolemia. J Clin Invest 1999; 104: 619-28.
129. Humphries SE, Hadfield G. Identifying patients with familial hypercholesterolaemia in primary care. Heart 2008; 94: 695-6.
130. Alonso R, Mata N, Castillo S, et al. Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 2008; 200: 315-321.
131. Hopkins PN. Familial hypercholesterolemia--improving treatment and meeting guidelines. Int J Cardiol 2003; 89: 13-23.
132. Malloy MJ, Kane JP. A risk factor for atherosclerosis: triglyceriderich lipoproteins. Adv Intern Med 2001; 47: 111-36.
133. Kolovou GD, Anagnostopoulou KK, Damaskos DS, et al. Gender influence on postprandial lipemia in heterozygotes for familial hypercholesterolemia. Ann Clin Lab Sci 2007; 37: 335-42.
134. Kolovou GD, Anagnostopoulou KK, Pilatis ND, et al. The influence of natural menopause on postprandial lipemia in heterozygotes for familial hypercholesterolemia. J Womens Health (Larchmt) 2004; 13: 1119-26.
135. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with non-fasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309-16.
136. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of MI, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
137. Bhattacharyya AK, Connor WE. Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest 1974; 53: 1033-43.
138. Patel SB, Salen G, Hidaka H, et al. Mapping a gene involved in regulating dietary cholesterol absorption. The sitosterolemia locus is found at chromosome 2p21. J Clin Invest 1998; 102: 1041-4.
139. Salen G, Shefer S, Nguyen L, Ness GC, Tint GS, Batta AK. Sitosterolemia. Subcell Biochem 1997; 28: 453-76.
140. Gregg RE, Connor WE, Lin DS, Brewer HB, Jr. Abnormal metabolism of shellfish sterols in a patient with sitosterolemia and xanthomatosis. J Clin Invest 1986; 77: 1864-72.
141. Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000; 290: 1771-5.
142. Velamakanni S, Janvilisri T, Shahi S, van Veen HW. A functional steroid-binding element in an ATP-binding cassette multidrug transporter. Mol Pharmacol 2008; 73:12-7.
143. Kolovou G, Voudris V, Drogari E, Palatianos G, Cokkinos DV. Coronary bypass grafts in a young girl with sitosterolemia. Eur Heart J 1996; 17: 965-6.
144. Rensen PC, van Berkel TJ. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride- rich lipid emulsions in vitro and in vivo. J Biol Chem 1996; 271: 14791-9.
145. Kolovou G, Daskalova D, Mikhailidis DP. Apolipoprotein E polymorphism and atherosclerosis. Angiology 2003; 54: 59-71.
146. Utermann G, Albrecht G, Steinmetz A. Polymorphism of apolipoprotein E. I. Methodological aspects and diagnosis of hyperlipoproteinemia type III without ultracentrifugation. Clin Genet 1978; 14: 351-8.
147. Kolovou GD, Daskalova D, Hatzivassiliou M, et al. The epsilon 2 and 4 alleles of apolipoprotein E and ischemic vascular events in the Greek population--implications for the interpretation of similar studies. Angiology 2003; 54: 51-8.
148. Kolovou GD, Anagnostopoulou KK, Salpea KD, et al. Apolipoprotein E genotype in matched men and women with coronary heart disease. Ann Clin Lab Sci 2005; 35: 391-6.
149. Kolovou GD, Anagnostopoulou KK, Mikhailidis DP, et al. Association of apolipoprotein E genotype with early onset of coronary heart disease in Greek men. Angiology 2005; 56: 663-70.
150. Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Apolipoprotein E gene polymorphism and and myocardial infarction. Int J Cardiol, 2009; 133: 264-65.
151. Kolovou GD, Anagnostopoulou KK. Apolipoprotein E polymorphism, age and coronary heart disease. Ageing Res Rev 2007; 6: 94-108.
152. van Bockxmeer FM, Mamotte CD, Gibbons FA, Burke V, Taylor RR. Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty. Circulation 1995; 92: 2066-71.
153. Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Apolipoprotein epsilon4 homozygosity and essential hypertension. South Med J 2004; 97: 1022.
154. Bennet AM, Di Angelantonio E, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007; 298: 1300-11.
155. Talmud PJ, Lewis SJ, Hawe E, et al. No APOEepsilon4 effect on coronary heart disease risk in a cohort with low smoking prevalence: the Whitehall II study. Atherosclerosis 2004; 177: 105-12.
156. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004; 141: 137-47.
157. Kolovou G, Yiannakouris N, Hatzivassiliou M, et al. Association of apolipoprotein E polymorphism with MI in Greek patients with coronary artery disease. Curr Med Res Opin 2002; 18: 118-24.
158. Rea IM, Mc Dowell I, McMaster D, Smye M, Stout R, Evans A. Apolipoprotein E alleles in non-agenarian subjects in the Belfast Elderly Longitudinal Free-living Ageing Study (BELFAST). Mech Ageing Dev 2001; 122: 1367-72.
159. Lahoz C, Schaefer EJ, Cupples LA, et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001; 154: 529-37.
160. Boerwinkle E, Utermann G. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am J Hum Genet 1988; 42: 104-12.
161. Lussier-Cacan S, Bolduc A, Xhignesse M, Niyonsenga T, Connelly PW, Sing CF. Impact of age and body size on inter-individual variation in measures of lipid metabolism: influence of gender and apolipoprotein E genotype. Clin Genet 2000; 57: 35-47.
162. Mahley RW, Pepin J, Palaoglu KE, Malloy MJ, Kane JP, Bersot TP. Low levels of high density lipoproteins in Turks, a population with elevated hepatic lipase. High density lipoprotein characterization and gender-specific effects of apolipoprotein e genotype. J Lipid Res 2000; 41: 1290-301.
163. Schaefer EJ, Lamon-Fava S, Johnson S, et al. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study. Arterioscler Thromb 1994; 14: 1105-13.
164. Somekawa Y, Wakabayashi A. Relationship between apolipoprotein E polymorphism, menopausal symptoms, and serum lipids during hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 1998; 79: 185-91.
165. Garry PJ, Baumgartner RN, Brodie SG, et al. Estrogen replacement therapy, serum lipids, and polymorphism of the apolipoprotein E gene. Clin Chem 1999; 45: 1214-23.
166. Frikke-Schmidt R, Tybjaerg-Hansen A, Steffensen R, Jensen G, Nordestgaard BG. Apolipoprotein E genotype: epsilon32 women are protected while epsilon43 and epsilon44 men are susceptible to ischemic heart disease: the Copenhagen City Heart Study. J Am Coll Cardiol 2000; 35: 1192-9.
167. Stengard JH, Frikke-Schmidt R, Tybjaerg-Hansen A, Nordestgaard BG, Sing CF. Variation in 5' promoter region of the APOE gene contributes to predicting ischemic heart disease (IHD) in the population at large: the Copenhagen City Heart Study. Ann Hum Genet 2007; 71: 762-71.
168. Boer JM, Ehnholm C, Menzel HJ, et al. Interactions between lifestyle- related factors and the ApoE polymorphism on plasma lipids and apolipoproteins. The EARS Study. European Atherosclerosis Research Study. Arterioscler Thromb Vasc Biol 1997; 17: 1675-81.
169. Izem L, Morton RE. Possible role for intracellular cholesteryl ester transfer protein in adipocyte lipid metabolism and storage. J Biol Chem 2007; 282: 21856-65.
170. Zhou H, Li Z, Silver DL, Jiang XC. Cholesteryl ester transfer protein (CETP) expression enhances HDL cholesteryl ester liver delivery, which is independent of scavenger receptor BI, LDL receptor related protein and possibly LDL receptor. Biochim Biophys Acta 2006; 1761: 1482-8.
171. Isaacs A, Aulchenko YS, Hofman A, et al. Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum highdensity lipoprotein cholesterol levels. J Clin Endocrinol Metab 2007; 92: 2680-7.
172. Isaacs A, Sayed-Tabatabaei FA, Hofman A, et al. The cholesteryl ester transfer protein I405V polymorphism is associated with increased high-density lipoprotein levels and decreased risk of MI: the Rotterdam Study. Eur J Cardiovasc Prev Rehabil 2007; 14: 419-21.
173. Hsieh MC, Tien KJ, Chang SJ, et al. Cholesteryl ester transfer protein B1B1 genotype as a predictor of coronary artery disease in Taiwanese with type 2 diabetes mellitus. Metabolism 2007; 56: 745-50.
174. Kolovou G, Anagnostopoulou K, Kostakou P, et al. Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and postprandial plasma lipoprotein levels in heterozygotes for familial hypercholesterolemia. Clin Chem Lab Med 2007; 45: 1190-8.
175. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study. Circulation 2000; 102: 2197-203.
176. Romanski SA, Nelson RM, Jensen MD. Meal fatty acid uptake in adipose tissue: gender effects in non-obese humans. Am J Physiol Endocrinol Metab 2000; 279: E455-62.
177. Jensen EV. On the mechanism of estrogen action. Perspect Biol Med 1962; 6: 47-59.
178. Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986; 320: 134-9.
179. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen receptor beta: an overview and update. Nucl Recept Signal 2008; 6: e003.
180. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925-30.
181. Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease. Endocr Rev 2004; 25: 869-98.
182. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 1999; 20: 358-417.
183. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 2000; 19: 4970-8.
184. Kimmins S, MacRae TH. Maturation of steroid receptors: an example of functional cooperation among molecular chaperones and their associated proteins. Cell Stress Chaperones 2000; 5: 76-86.
185. McKay LI, Cidlowski JA. Molecular control of immune/ inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 1999; 20: 435-59.
186. Ho CC, Ling YC, Chang LW, Tsai HT, Tsai MH, Lin P. 17-Beta estradiol and hydroxyestradiols interact via the NF-kappa B pathway to elevate cyclooxygenase 2 expression and prostaglandin E2 secretion in human bronchial epithelial cells. Toxicol Sci 2008; 104: 294-302.
187. Alevizaki M, Saltiki K, Cimponeriu A, et al. Severity of cardiovascular disease in postmenopausal women: associations with common estrogen receptor alpha polymorphic variants. Eur J Endocrinol 2007; 156: 489-96.
188. Xu H, Hou X, Wang N, et al. Gender-specific effect of estrogen receptor-1 gene polymorphisms in coronary artery disease and its angiographic severity in Chinese population. Clin Chim Acta 2008; 395: 130-3.
189. Molvarec A, Szeplaki G, Kovacs M, et al. Estrogen receptor alpha (ESR1) PvuII and XbaI gene polymorphisms in ischemic stroke in a Hungarian population. Clin Chim Acta 2007; 382: 100-5.
190. Molvarec A, Nagy B, Kovacs M, et al. Lipid, haemostatic and inflammatory variables in relation to the estrogen receptor alpha (ESR1) PvuII and XbaI gene polymorphisms. Clin Chim Acta 2007; 380: 157-64.
191. Schuit SC, Oei HH, Witteman JC, et al. Estrogen receptor alpha gene polymorphisms and risk of MI. JAMA 2004; 291: 2969-77.
192. Peter I, Kelley-Hedgepeth A, Fox CS, et al. Variation in estrogenrelated genes associated with cardiovascular phenotypes and circulating estradiol, testosterone, and dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab 2008; 93: 2779-85.
193. Peter I, Huggins GS, Shearman AM, et al. Age-related changes in echocardiographic measurements: association with variation in the estrogen receptor-alpha gene. Hypertension 2007; 49: 1000-6.
194. Peter I, Shearman AM, Vasan RS, et al. Association of estrogen receptor beta gene polymorphisms with left ventricular mass and wall thickness in women. Am J Hypertens 2005; 18: 1388-95.
195. Shearman AM, Cupples LA, Demissie S, et al. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 2003; 290: 2263-70.
196. Cooper JA, Miller GJ, Bauer KA, et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000; 102: 2816-22.
197. Jakimiuk A, Nowicka M, Bogusiewicz M, et al. Prevalence of estrogen receptor alpha PvuII and XbaI polymorphism in popula tion of Polish postmenopausal women. Folia Histochem Cytobiol 2007; 45: 331-8.
198. Keavney B, Palmer A, Parish S, et al. Lipid-related genes and MI in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk. Int J Epidemiol 2004; 33: 1002-13.
199. Fox CS, Yang Q, Cupples LA, et al. Sex-specific association between estrogen receptor-alpha gene variation and measures of adiposity: the Framingham Heart Study. J Clin Endocrinol Metab 2005; 90: 6257-62.
200. Shearman AM, Cooper JA, Kotwinski PJ, et al. Estrogen receptor alpha gene variation is associated with risk of MI in more than seven thousand men from five cohorts. Circ Res 2006; 98: 590-2.
201. Lehtimaki T, Kunnas TA, Mattila KM, et al. Coronary artery wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study. J Mol Med 2002; 80: 176-80.
202. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005; 146: 624-32.
203. Filardo EJ, Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab 2005; 16: 362-7.
204. Filardo E, Quinn J, Pang Y, et al. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 2007; 148: 3236-45.
205. Haas E, Meyer MR, Schurr U, et al. Differential effects of 17betaestradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 2007; 49: 1358-63.
206. Krieger N, Lowy I, Aronowitz R, et al. Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives. J Epidemiol Community Health 2005; 59: 740-8.
207. Birkhauser MH, Panay N, Archer DF, et al. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008; 11: 108-23.
208. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
209. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-9.
210. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49-57.
211. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84: 961-7.
212. Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007; 335: 239.
213. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-37.
214. Shakir YA, Samsioe G, Nyberg P, Lidfeldt J, Nerbrand C. Cardiovascular risk factors in middle-aged women and the association with use of hormone therapy: results from a population-based study of Swedish women. The Women's Health in the Lund Area (WHILA) Study. Climacteric 2004; 7: 274-83.
215. Menon DV, Vongpatanasin W. Effects of transdermal estrogen replacement therapy on cardiovascular risk factors. Treat Endocrinol 2006; 5: 37-51.
216. Lewandowski KC, Komorowski J, Mikhalidis DP, et al. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab 2006; 91: 3123-30.
217. Prelevic GM, Kocjan T, Markou A. Hormone replacement therapy in postmenopausal women. Minerva Endocrinol 2005; 30: 27-36.
218. Stojanovic ND, Kwong P, Byrne DJ, et al. The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study. Angiology 2003; 54: 391-9.
219. Prelevic GM, Kwong P, Byrne DJ, Jagroop IA, Ginsburg J, Mikhailidis DP. A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002; 77: 945-51.